Now showing items 1-2 of 2

  • The clinical meaningfulness of ADAS-Cog changes in Alzheimer’s disease patients treated with donepezil in an open-label trial 

    Rockwood, K., Fay, S., Gorman, M., Carver, D., & Graham, J. E. (2007). The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurology, 7(1), 26. doi:10.1186/1471-2377-7-26
    Background: In 6-month anti-dementia drug trials, a 4-point change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is held to be clinically important. We examined how this change compared with ...
  • Frailty, fitness and late-life mortality in relation to chronological and biological age 

    Mitnitski, A. B., Graham, J. E., Mogilner, A. J., & Rockwood, K. (2002). Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatrics, 2, 1. https://doi.org/10.1186/1471-2318-2-1
    Background: People age at remarkably different rates, but how to estimate trajectories of senescence is controversial. Methods: In a secondary analysis of a representative cohort of Canadians aged 65 and over (n = 2914) ...